#	Pagina
attuale pagina	/open-h2020/projects/205623/index.html

Opendata, web and dolomites

GlySign SIGNED

Exploitation of Glycosylation Signatures for Precision Medicine

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

GlySign project word cloud

Explore the words cloud of the GlySign project. It provides you a very rough idea of what is the project "GlySign" about.

rheumatoid distinctive instrumental academia close mobility gap glycans lack adding thrombocytopenia diagnostic healthy biomarkers glycan chemists inflammatory push diabetes subtype young disease samples clinicians network selective implicating glycoproteins patients discovery industrial vitro academic signatures skills model translation sensitive clinical medicine fill proteins six tools experts neonatal slow immense clinically variety progression complexity glycosylation industry circulating cancer arthritis scientists technologies diseases glysign training chronic final controls alloimmune structural pm beneficiaries innovative ing precision fetal platforms profiles translational establishing prostate market human glycomic glycoanalytical prognostic glycomics

Project "GlySign" data sheet

The following table provides information about the project.

Coordinator	ACADEMISCH ZIEKENHUIS LEIDEN Organization address address: ALBINUSDREEF 2 city: LEIDEN postcode: 2333 ZA website: www.lumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Project website	http://www.glysign.eu/
Total cost	1˙552˙846 €
EC max contribution	1˙552˙846 € (100%)
Programme	1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
Code Call	H2020-MSCA-ITN-2016
Funding Scheme	MSCA-ITN-EID
Starting year	2016
Duration (year-month-day)	from 2016-10-01 to 2020-09-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	ACADEMISCH ZIEKENHUIS LEIDEN ACADEMISCH ZIEKENHUIS LEIDEN Organization address address: ALBINUSDREEF 2 city: LEIDEN postcode: 2333 ZA website: www.lumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (LEIDEN)	coordinator	510˙748.00
2	LUDGER LIMITED LUDGER LIMITED Organization address address: CULHAM SCIENCE CENTRE - BUILDING E1 city: ABINGDON postcode: OX14 3EB website: www.ludger.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (ABINGDON)	participant	546˙575.00
3	GENOS DOO ZA VJESTACENJE I ANALIZU GENOS DOO ZA VJESTACENJE I ANALIZU Organization address address: VATROGASNA 112 city: OSIJEK postcode: 31000 website: www.genos.hr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	HR (OSIJEK)	participant	495˙522.00
4	ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM Organization address address: MEIBERGDREEF 15 city: AMSTERDAM postcode: 1105AZ website: www.amc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (AMSTERDAM)	partner	0.00
5	MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV Organization address address: HOFGARTENSTRASSE 8 city: MUENCHEN postcode: 80539 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MUENCHEN)	partner	0.00
6	PROZOMIX LIMITED PROZOMIX LIMITED Organization address address: STATION COURT 3 city: HALTWHISTLE postcode: NE49 9HN website: www.prozomix.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (HALTWHISTLE)	partner	0.00
7	Stichting Sanquin Bloedvoorziening Stichting Sanquin Bloedvoorziening Organization address address: Plesmanlaan 125 city: Amsterdam postcode: 1006 AN website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (Amsterdam)	partner	0.00

Map

Project objective

GlySign is a research training network for the translation of glycomic clinical biomarkers for Precision Medicine (PM). Complex, distinctive changes occur in the glycomics profiles or - Glycan Signatures - of human glycoproteins during progression of many chronic diseases including cancer and inflammatory conditions. The three beneficiaries of the GlySign Consortium have been instrumental in contributing to knowledge in this field through development of glycomics technology and discovery of clinically important novel glycan biomarkers in a variety of diseases. Glycan signatures have great potential for adding useful diagnostic and prognostic information in PM. However, advancement of this field is slow because (a) glycans have immense structural complexity resulting in major technical challenges for their analysis and (b) there is a lack of experts with required glycoanalytical skills. GlySign will address this gap by training six young scientists within an innovative training-by-research programme with high industrial-academic mobility to eventually push forward the translation of novel glycomics-based diagnostic tools into clinical practice. This will be achieved by further developing a range of selective and sensitive glycomics technologies for the analysis of samples from patients and healthy controls in close collaboration between industry/academia as well as clinical chemists and clinicians who will be the end users of GlySign’s final products. To this end, we will focus the training on clinical glycomics applied to four model diseases implicating changes in the glycosylation of circulating proteins specific to disease progression or subtype, i.e. diabetes, prostate cancer, fetal and neonatal alloimmune thrombocytopenia and rheumatoid arthritis. Due to its strong industrial and translational focus, GlySign will, moreover, fill a current gap in the market by establishing new in vitro diagnostic platforms for clinical exploitation of glycomic biomarkers for PM.

Deliverables

List of deliverables.
Website established	Websites, patent fillings, videos etc.	2019-03-20 15:56:20

Take a look to the deliverables list in detail: detailed list of GlySign deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2019	Eric Adua, Elham Memarian, Alyce Russell, Irena TrbojeviÄ‡-AkmaÄiÄ‡, Ivan Gudelj, Julija JuriÄ‡, Peter Roberts, Gordan Lauc, Wei Wang Utilization of N-glycosylation profiles as risk stratification biomarkers for suboptimal health status and metabolic syndrome in a Ghanaian population published pages: 1273-1287, ISSN: 1752-0363, DOI: 10.2217/bmm-2019-0005	Biomarkers in Medicine 13/15	2020-02-06
2020	Clemens Wittenbecher, Tamara Å tambuk, Olga Kuxhaus, Najda Rudman, Frano VuÄkoviÄ‡, Jerko Å tambuk, Catarina Schiborn, Dario RaheliÄ‡, Stefan Dietrich, Olga Gornik, Markus Perola, Heiner Boeing, Matthias B. Schulze, Gordan Lauc Plasma N -Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study published pages: dc191507, ISSN: 0149-5992, DOI: 10.2337/dc19-1507	Diabetes Care	2020-02-06
2019	Tanya M. Monaghan, Maja PuÄiÄ‡-BakoviÄ‡, Frano VuÄkoviÄ‡, Christine Lee, Dina Kao, Iwona WÃ³jcik, Filip KliÄek, Christos Polytarchou, Brandi Roach, Tom Louie, Peter Kim, Brandi Roach, Christos Polytarchou, Marcin Frankowski, Gordan Lauc Decreased Complexity of Serum N-glycan Structures Associates with Successful Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection published pages: 1676-1678.e3, ISSN: 0016-5085, DOI: 10.1053/j.gastro.2019.08.034	Gastroenterology 157/6	2020-02-06
2019	Najda Rudman, Olga Gornik, Gordan Lauc Altered Nâ€glycosylation profiles as potential biomarkers and drug targets in diabetes published pages: 1598-1615, ISSN: 0014-5793, DOI: 10.1002/1873-3468.13495	FEBS Letters 593/13	2020-02-06
2019	Jiaonan Liu, Mamatyusupu Dolikun, Jerko Å tambuk, Irena TrbojeviÄ‡-AkmaÄiÄ‡, Jie Zhang, Jinxia Zhang, Hao Wang, Xiaoni Meng, Genadij Razdorov, Desmond Menon, Deqiang Zheng, Lijuan Wu, Youxin Wang, Manshu Song, Gordan Lauc, Wei Wang Glycomics for Type 2 Diabetes Biomarker Discovery: Promise of Immunoglobulin G Subclass-Specific Fragment Crystallizable N-glycosylation in the Uyghur Population published pages: 640-648, ISSN: 1557-8100, DOI: 10.1089/omi.2019.0052	OMICS: A Journal of Integrative Biology 23/12	2020-02-06
2017	Xia Shen, Lucija KlariÄ‡, Sodbo Sharapov, Massimo Mangino, Zheng Ning, Di Wu, Irena TrbojeviÄ‡-AkmaÄiÄ‡, Maja PuÄiÄ‡-BakoviÄ‡, Igor Rudan, Ozren PolaÅ¡ek, Caroline Hayward, Timothy D. Spector, James F. Wilson, Gordan Lauc, Yurii S. Aulchenko Multivariate discovery and replication of five novel loci associated with Immunoglobulin G N-glycosylation published pages: , ISSN: 2041-1723, DOI: 10.1038/s41467-017-00453-3	Nature Communications 8/1	2019-04-18
2019	Eric Adua, Elham Memarian, Alyce Russell, Irena TrbojeviÄ‡-AkmaÄiÄ‡, Ivan Gudelj, Julija JuriÄ‡, Peter Roberts, Gordan Lauc, Wei Wang High throughput profiling of whole plasma N-glycans in type II diabetes mellitus patients and healthy individuals: A perspective from a Ghanaian population published pages: 10-21, ISSN: 0003-9861, DOI: 10.1016/j.abb.2018.10.015	Archives of Biochemistry and Biophysics 661	2019-04-18
2018	Zejian Zhang, Manfred Wuhrer, Stephanie Holst Serum sialylation changes in cancer published pages: 139-160, ISSN: 0282-0080, DOI: 10.1007/s10719-018-9820-0	Glycoconjugate Journal 35/2	2019-04-18
2018	Cristina Menni, Ivan Gudelj, Erin Macdonald-Dunlop, Massimo Mangino, Jonas Zierer, Erim BeÅ¡iÄ‡, Peter K. Joshi, Irena TrbojeviÄ‡-AkmaÄiÄ‡, Phil J. Chowienczyk, Tim D. Spector, James F. Wilson, Gordan Lauc, Ana M. Valdes Glycosylation Profile of Immunoglobulin G Is Cross-Sectionally Associated With Cardiovascular Disease Risk Score and Subclinical Atherosclerosis in Two Independent Cohorts published pages: 1555-1564, ISSN: 0009-7330, DOI: 10.1161/CIRCRESAHA.117.312174	Circulation Research 122/11	2019-04-18
2018	Ivan Gudelj, Perttu P. Salo, Irena TrbojeviÄ‡-AkmaÄiÄ‡, Malena Albers, Dragan Primorac, Markus Perola, Gordan Lauc Low galactosylation of IgG associates with higher risk for future diagnosis of rheumatoid arthritis during 10â€¯years of follow-up published pages: 2034-2039, ISSN: 0925-4439, DOI: 10.1016/j.bbadis.2018.03.018	Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1864/6	2019-04-18

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLYSIGN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLYSIGN" are provided by the European Opendata Portal: CORDIS opendata.